Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.5.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.3.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.4.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
ED.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.426NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.399NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.337NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.539NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.35NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.54NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.164NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KY.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.392NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BG.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JF.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.572NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.397NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Q.3 (Alpha)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.523NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.116 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.38 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.595.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.340NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.437NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.452NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.400NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.2.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.16 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.46.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.37 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.336NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.377NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.5.3 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BB.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.86 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.7 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.12 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.7.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used